(Q36709731)

15 August 2017

1 reference

title

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform (English)

1 reference

15 August 2017

Hervé Poulet

1

1 reference

15 August 2017

Jules Minke

2

1 reference

15 August 2017

Maria Camila Pardo

3

1 reference

15 August 2017

Véronique Juillard

4

1 reference

15 August 2017

Bob Nordgren

5

1 reference

15 August 2017

Jean-Christophe Audonnet

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

8 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

25

1 reference

15 August 2017

30

1 reference

15 August 2017

5606-5612

1 reference

Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Rationale and perspectives on the success of vaccination against bovine herpesvirus-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Protective immunity against avian influenza induced by a fowlpox virus recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Efficacy studies on a canarypox-rabies recombinant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Recombinant fowlpox virus inducing protective immunity in non-avian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Efficacy of a canarypox virus-vectored vaccine against feline leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Safety profile of recombinant canarypox HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Avipoxvirus multiplication in a mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Cowpox: reservoir hosts and geographic range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Recombinant nipah virus vaccines protect pigs against challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

inferred from DOI database lookup

7 January 2021

based on heuristic

Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.066

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.11.066

1 reference

15 August 2017

1 reference